In a humanized mouse model, we provided evidence supporting the ability of CD133+/CXCR4+ CSCs-enriched spheres (from here-on named CSC spheres) to initiate bone metastases, that clinically occurred in approximately 30–40% of NSCLC patients [22]. This evidence concerns the gene CXCR4 and non-small cell lung carcinoma.